Bringing microbial CDMO expertise to Festival of Biologics 2026, Basel

Langenfeld, Germany – ARTES Biotechnology, the German-based biopharmaceutical CDMO for microbial cell lines and process development, will make its first appearance as an exhibitor and attendee at the Festival of Biologics, Europe’s largest biologics event, this October in Basel, Switzerland.

ARTES will be on Stand 232 for the three-day event, organized by Terrapinn.

A first-time exhibitor looking to connect

Attending for the first time, ARTES is looking forward to connecting with researchers, pharma teams, biotech leaders, investors, and everyone in between who is shaping the future of biologics. The Festival of Biologics brings together the full spectrum of the industry, from discovery and development through clinical trials, manufacturing, market access and fill & finish, making it a natural fit for a CDMO built around helping partners move target proteins from concept to production.

Microbial expression expertise on show

Visitors to the ARTES stand will be able to learn more about the company’s technology platforms for developing microbial recombinant cell lines and production processes for a wide range of target products, including vaccines, biopharmaceuticals, biosimilars, and enzymes. ARTES also offers a broad portfolio of pre-developed, readily transferable processes, giving partners a faster route from target molecule to manufacturing-ready process.

The delegation from ARTES, Managing Director Dr. Michael Piontek and Business Development Director Dr. Melanie Piontek, will be on hand throughout the event to discuss the company’s microbial production platforms and explore new partnerships with visitors to the show.

About ARTES Biotechnology

ARTES Biotechnology GmbH is a German company specialized in the development of processes for the production of recombinant proteins from microbial expression systems. In particular, the company offers the development of optimized production cell lines and processes based on yeast (Hansenula, Pichia, Saccharomyces) and bacteria (E. coli). The expression platforms are complemented by a unique virus-like particle (VLP) technology for antigen presentation and vaccine development. For more than 20 years, ARTES has successfully partnered with human and animal health companies, enzyme manufacturers, and the cosmetics, diagnostics, and nutrition industries. The company operates worldwide from its 1,000 sqm facility in Langenfeld, Germany.

More information at www.artes-biotechnology.com

About Festival of Biologics 2026

The Festival of Biologics is Europe’s largest biologics event, covering the full arc of the industry from discovery and development through clinical trials, manufacturing, market access and fill & finish, with a particular focus on antibody therapies, cell and gene therapies, immunotherapies and biosimilars. The event brings together more than 3,000 attendees, 350 speakers and 150 exhibitors across pharma, biotech, academia, regulation, and investment.

Festival of Biologics 2026 is a three-day event running October 13-15 at Hall 1, Messe Basel, in Switzerland, with a conference programme spanning 13 tracks alongside the exhibition floor.

The event is organized by Terrapinn, with further information at: https://www.terrapinn.com/conference/festival-of-biologics/index.stm

Resources

Click on ARTES Microbial Cell Line Development to learn more.